The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the FDA, and Orphan Drug Designation for the treatment of ARID1a-deficient ...

Hargreaves will now investigate whether the immunotherapy-boosting effect of mutated ARID1A extends to SWI/SNF mutations more generally, as well as test whether SWI/SNF-blocking drugs could ...